Stocks and Investing Stocks and Investing
Wed, March 1, 2023

Vamil Divan Initiated (TVTX) at Strong Buy and Held Target at $37 on, Mar 1st, 2023


Published on 2024-10-28 01:59:37 - WOPRAI, Vamil Divan
  Print publication without navigation


Vamil Divan of Guggenheim, Initiated "Travere Therapeutics, Inc." (TVTX) at Strong Buy and Held Target at $37 on, Mar 1st, 2023.

Vamil has made no other calls on TVTX in the last 4 months.



There are 6 other peers that have a rating on TVTX. Out of the 6 peers that are also analyzing TVTX, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Alex Thompson of "Stifel" Initiated at Hold and Held Target at $22 on, Wednesday, December 14th, 2022


These are the ratings of the 5 analyists that currently disagree with Vamil


  • Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $42 on, Tuesday, February 28th, 2023
  • Ed Arce of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $40 on, Friday, February 24th, 2023
  • Carter Gould of "Barclays" Maintained at Buy with Decreased Target to $31 on, Tuesday, February 21st, 2023
  • Do Kim of "Piper Sandler" Maintained at Buy with Increased Target to $46 on, Tuesday, February 21st, 2023
  • Laura Chico of "Wedbush" Upgraded from Hold to Buy and Held Target at $30 on, Tuesday, February 21st, 2023
Contributing Sources